Citi raised the firm’s price target on Zymeworks (ZYME) to $22 from $19 and keeps a Buy rating on the shares. The firm believes Zanidatamab is gaining traction in biliary tract cancer with the HERIZON data in late Q4 as the next catalyst for the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks Reports Strong Q2 2025 Financial Performance
- Zymeworks: Strong Financial Performance and Promising Pipeline Drive Buy Rating
- Zymeworks’ Strategic Financial Management and Promising Pipeline Drive Buy Rating
- Zymeworks reports Q2 EPS 3c, consensus (46c)
- Zymeworks Reports Q2 Results and FDA Clearance